Epilepsy in pregnancy

References

1. ↵
   1. Fiest KM,
   2. Sauro KM,
   3. Wiebe S,
   4. Patten SB,
   5. Kwon CS,
   6. Dykeman J,
   7. et al.

   (2017) Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology 88, 296–303.
2. ↵
   1. Al Rajeh S,
   2. Awada A,
   3. Bademosi O,
   4. Ogunniyi A

   (2001) The prevalence of epilepsy and other seizure disorders in an Arab population: a community-based study. Seizure 10, 410–414.
3. ↵
   1. Harden CL,
   2. Pennell PB

   (2013) Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol 12, 72–83.
4. ↵
   1. Pennell PB

   (2013) Pregnancy, epilepsy, and women's issues. Continuum (Minneap Minn) 19, 697–714.
5. ↵
   1. Fujimura K,
   2. Mitsuhashi T,
   3. Takahashi T

   (2017) Adverse effects of prenatal and early postnatal exposure to antiepileptic drugs: Validation from clinical and basic researches. Brain Dev 39, 635–643.
6. ↵
   1. Tomson T,
   2. Landmark CJ,
   3. Battino D

   (2013) Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 54, 405–414.
7. ↵
   1. Harden CL,
   2. Meador KJ,
   3. Pennell PB,
   4. Hauser WA,
   5. Gronseth GS,
   6. French JA,
   7. et al.

   (2009) Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73, 133–141.
8. ↵
   1. Nunes VD,
   2. Sawyer L,
   3. Neilson J,
   4. Sarri G,
   5. Cross JH

   (2012) Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ 344, e281.
9. 1. Alaqeel A,
   2. Sabbagh AJ

   (2013) Epilepsy;what do Saudi's living in Riyadh know? Seizure 22, 205–209.
10. ↵
    1. Battino D,
    2. Tomson T,
    3. Bonizzoni E,
    4. Craig J,
    5. Lindhout D,
    6. Sabers A,
    7. et al.

    (2013) Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia 54, 1621–1627.
11. ↵
    1. He S,
    2. Zhu H,
    3. Qiu X,
    4. Zhu X,
    5. Peng A,
    6. Duan J,
    7. et al.

    (2017) Pregnancy outcome in women with epilepsy in Western China: A prospective hospital based study. Epilepsy Behav 74, 10–14.
12. ↵
    1. Kamyar M,
    2. Varner M

    (2013) Epilepsy in pregnancy. Clin Obstet Gynecol 56, 330–341.
13. ↵
    1. Cagnetti C,
    2. Lattanzi S,
    3. Foschi N,
    4. Provinciali L,
    5. Silvestrini M

    (2014) Seizure course during pregnancy in catamenial epilepsy. Neurology 83, 339–344.
14. ↵
    1. Borthen I

    (2015) Obstetrical complications in women with epilepsy. Seizure 28, 32–34.
15. ↵
    1. Amudhan S,
    2. Gururaj G,
    3. Satishchandra P

    (2015) Epilepsy in India II: Impact, burden, and need for a multisectoral public health response. Ann Indian Acad Neurol 18, 369–381.
16. ↵
    1. Harden CL,
    2. Hopp J,
    3. Ting TY,
    4. Pennell PB,
    5. French JA,
    6. Hauser WA,
    7. et al.

    (2009) Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73, 126–132.
17. ↵
    1. Viale L,
    2. Allotey J,
    3. Cheong-See F,
    4. Arroyo-Manzano D,
    5. Mccorry D,
    6. Bagary M,
    7. et al.

    (2015) Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis. Lancet 386, 1845–1852.
18. ↵
    1. Farmen AH,
    2. Grundt J,
    3. Tomson T,
    4. Nakken KO,
    5. Nakling J,
    6. Mowinchel P,
    7. et al.

    (2015) Intrauterine growth retardation in foetuses of women with epilepsy. Seizure 28, 76–80.
19. ↵
    1. Hernández-Díaz S,
    2. McElrath TF,
    3. Pennell PB,
    4. Hauser WA,
    5. Yerby M,
    6. Holmes LB,
    7. et al.

    (2017) Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol 82, 457–465.
20. ↵
    1. Thomas SV,
    2. Jose M,
    3. Divakaran S,
    4. Sankara Sarma P

    (2017) Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia 58, 274–281.
21. ↵
    1. Hernández-Díaz S,
    2. Smith CR,
    3. Shen A,
    4. Mittendorf R,
    5. Hauser WA,
    6. Yerby M,
    7. et al.

    (2012) Comparative safety of antiepileptic drugs during pregnancy. Neurology 78, 1692–1699.
22. ↵
    1. Vajda FJ,
    2. O'Brien TJ,
    3. Lander CM,
    4. Graham J,
    5. Eadie MJ

    (2014) The teratogenicity of the newer antiepileptic drugs - an update. Acta Neurol Scand 130, 234–238.
23. 1. Veiby G,
    2. Daltveit AK,
    3. Engelsen BA,
    4. Gilhus NE

    (2014) Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 261, 579–588.
24. ↵
    1. Campbell E,
    2. Kennedy F,
    3. Russell A,
    4. Smithson WH,
    5. Parsons L,
    6. Morrison PJ,
    7. et al.

    (2014) Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 85, 1029–1034.
25. ↵
    1. Weston J,
    2. Bromley R,
    3. Jackson CF,
    4. Adab N,
    5. Clayton-Smith J,
    6. Greenhalgh J,
    7. et al.

    (2016) Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 11, CD010224.
26. ↵
    1. Samrén EB,
    2. van Duijn CM,
    3. Christiaens GC,
    4. Hofman A,
    5. Lindhout D

    (1999) Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 46, 739–746.
27. ↵
    1. Vajda FJ,
    2. Graham J,
    3. Roten A,
    4. Lander CM,
    5. O'Brien TJ,
    6. Eadie M

    (2012) Teratogenicity of the newer antiepileptic drugs - the Australian experience. J Clin Neurosci 19, 57–59.
28. ↵
    1. Morrow J,
    2. Russell A,
    3. Guthrie E,
    4. Parsons L,
    5. Robertson I,
    6. Waddell R,
    7. et al.

    (2006) Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77, 193–198.
29. ↵
    1. Wlodarczyk BJ,
    2. Palacios AM,
    3. George TM,
    4. Finnell RH

    (2012) Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A 158A, 2071–2090.
30. ↵
    1. Hegde A,
    2. Kaur A,
    3. Sood A,
    4. Dhanorkar M,
    5. Varma HT,
    6. Singh G,
    7. et al.

    (2017) Fetal Hydantoin Syndrome. J Pediatr 188, 304.
31. ↵
    1. Hanson JW

    (1986) Teratogen update: Fetal hydantoin effects. Teratology 33, 349–353.
32. ↵
    1. Veroniki AA,
    2. Cogo E,
    3. Rios P,
    4. Straus SE,
    5. Finkelstein Y,
    6. Kealey R,
    7. et al.

    (2017) Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med 15, 95.
33. ↵
    1. Gerard EE,
    2. Meador KJ

    (2016) Managing Epilepsy in Women. Continuum (Minneap Minn) 22, 204–226.
34. ↵
    1. Diav-Citrin O,
    2. Shechtman S,
    3. Bar-Oz B,
    4. Cantrell D,
    5. Arnon J,
    6. Ornoy A

    (2008) Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect. CNS Drugs 22, 325–334.
35. ↵
    1. Kondo T,
    2. Kaneko S,
    3. Amano Y,
    4. Egawa I

    (1996) Preliminary Report on Teratogenic Effects of Zonisamide in the Offspring of Treated Women with Epilepsy. Epilepsia 37, 1242–1244.
36. ↵
    1. Hernández-Díaz S,
    2. Mittendorf R,
    3. Smith CR,
    4. Hauser WA,
    5. Yerby M,
    6. Holmes LB,
    7. et al.

    (2014) Association Between Topiramate and Zonisamide Use During Pregnancy and Low Birth Weight. Obstetrics & Gynecology 123, 21–28.
37. ↵
    1. Hoeltzenbein M,
    2. Supcun-Ritzler S,
    3. Langthaler M,
    4. Daumer-Haas C,
    5. Schaefer C

    (2011) Lacosamide during pregnancy: Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Reproductive Toxicology 31, 259–259.
38. ↵
    1. Lattanzi S,
    2. Cagnetti C,
    3. Foschi N,
    4. Provinciali L,
    5. Silvestrini M

    (2017) Lacosamide during pregnancy and breastfeeding. Neurol Neurochir Pol 51, 266–269.
39. ↵
    1. Khaleghi F,
    2. Nemec EC

    (2017) Brivaracetam (Briviact): A Novel Adjunctive Therapy for Partial-Onset Seizures. P T 42, 92–96.
40. ↵
    1. Stephen LJ,
    2. Brodie MJ

    (2018) Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Ther Adv Neurol Disord 11, 1.
41. ↵
    1. Rohracher A,
    2. Brigo F,
    3. Höfler J,
    4. Kalss G,
    5. Neuray C,
    6. Dobesberger J,
    7. et al.

    (2016) Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother 17, 1403–1411.
42. ↵
    1. Costa R,
    2. Magalhães LM,
    3. Graça J,
    4. Vieira M,
    5. Gama H,
    6. Moreira J,
    7. et al.

    (2018) Eslicarbazepine acetate exposure in pregnant women with epilepsy. Seizure 58, 72–74.
43. ↵
    1. Gerard EE,
    2. Meador KJ

    (2015) An Update on Maternal Use of Antiepileptic Medications in Pregnancy and Neurodevelopment Outcomes. J Pediatr Genet 4, 94–110.
44. ↵
    1. Harden CL,
    2. Pennell PB,
    3. Koppel BS,
    4. Hovinga CA,
    5. Gidal B,
    6. Meador KJ,
    7. et al.

    (2009) Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73, 142–149.